InflaRx Overview
- Year Founded
-
2007
- Status
-
Public
- Employees
-
65
- Stock Symbol
-
IFRX
- Share Price
-
$1.11
- (As of Wednesday Closing)
InflaRx General Information
Description
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
Contact Information
Website
www.inflarx.deCorporate Office
- Winzerlaer Street 2
- 07745 Jena
- Germany
Corporate Office
- Winzerlaer Street 2
- 07745 Jena
- Germany
InflaRx Stock Performance
As of 18-Nov-2026, InflaRx’s stock price is $1.11. Its current market cap is $164M with 147M shares.
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.11 | $1.15 | $0.80 - $2.95 | $164M | 147M | 867K | -$0.37 |
InflaRx Financials Summary
As of 30-Sep-2026, InflaRx has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 85,210 | 17,191 | 81,788 | (24,258) |
| Revenue | 0 | 33 | 179 | 68 |
| EBITDA | (36,780) | (53,026) | (52,753) | (49,634) |
| Net Income | (34,070) | (51,475) | (49,846) | (46,169) |
| Total Assets | 182,938 | 64,858 | 79,103 | 132,879 |
| Total Debt | 919 | 1,055 | 838 | 1,238 |
InflaRx Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
InflaRx Comparisons
Industry
Financing
Details
InflaRx Competitors (49)
One of InflaRx’s 49 competitors is OncoResponse, a Venture Capital-Backed company based in Houston, TX.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| OncoResponse | Venture Capital-Backed | Houston, TX | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| XBiotech | Corporation | Austin, TX | ||||
| Vir Biotechnology | Formerly VC-backed | San Francisco, CA |
InflaRx Patents
InflaRx Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2026529093-A | Condensed piperidinyl bicyclic compounds and related compounds for use in the treatment of diseases | Pending | 16-Aug-2023 | ||
| AU-2024324780-A1 | Fused piperidinyl bicyclic and related compounds for use in the treatment of diseases | Pending | 16-Aug-2023 | ||
| EP-4761731-A1 | Fused piperidinyl bicyclic and related compounds for use in the treatment of diseases | Pending | 16-Aug-2023 | ||
| WO-2025037010-A1 | Fused piperidinyl bicyclic and related compounds for use in the treatment of diseases | Inactive | 16-Aug-2023 | ||
| US-12180274-B2 | Treatment of pneumonia and ards with inhibitors of c5a and il-6 activity | Active | 26-May-2023 | C07K16/248 |
InflaRx Signals
InflaRx ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
InflaRx FAQs
-
When was InflaRx founded?
InflaRx was founded in 2007.
-
Where is InflaRx headquartered?
InflaRx is headquartered in Jena, Germany.
-
What is the size of InflaRx?
InflaRx has 65 total employees.
-
What industry is InflaRx in?
InflaRx’s primary industry is Drug Discovery.
-
Is InflaRx a private or public company?
InflaRx is a Public company.
-
What is InflaRx’s stock symbol?
The ticker symbol for InflaRx is IFRX.
-
What is the current stock price of InflaRx?
As of 18-Nov-2026 the stock price of InflaRx is $1.11.
-
What is the current market cap of InflaRx?
The current market capitalization of InflaRx is $164M.
-
Who are InflaRx’s competitors?
OncoResponse, CytomX Therapeutics, Kite Pharma, XBiotech, and Vir Biotechnology are some of the 49 competitors of InflaRx.
-
What is InflaRx’s annual earnings per share (EPS)?
InflaRx’s EPS for 12 months was -$0.37.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process